Amphetamines in child medicine: a review of ClinicalTrials.gov

Frontiers in Pharmacology

Pharmacology

Omar E. Hegazi¹  Moyad Shahwan¹  Samer O. Alalalmeh¹  Nasser M. Alorfi²  Alanood S. Algarni²  Fahad S. Alshehri²  Ahmed M. Ashour² 

[1] Center of Medical and Bio-Allied Health Sciences Research, Ajman University, Ajman, United Arab Emirates;Department of Clinical Sciences, College of Pharmacy and Health Sciences, Ajman University, Ajman, United Arab Emirates;Department of Pharmacology and Toxicology, College of Pharmacy, Umm Al-Qura University, Makkah, Saudi Arabia;

关键词: amphetamines;    pediatric medicine;    ADHD;    dependency;    developing brain;    clinical trials;   

DOI  :  10.3389/fphar.2023.1280562

 received in 2023-08-20, accepted in 2023-09-18,  发布年份 2023

来源: Frontiers

【 摘 要 】

Background: Globally, the use of amphetamines as therapeutic agents in pediatric medicine is a crucial area of concern, especially given the population’s vulnerability.Methods: On 6 August 2023, a search was conducted on ClinicalTrials.gov using “amphetamine” as the keyword. Two independent examiners screened trials against set criteria, including a focus on amphetamine, completion status, an interventional approach, and included children. Ongoing or observational studies were excluded. Data extracted from the qualified trials encompassed primary objectives, participant counts, study duration, and outcomes, with the aim of analyzing children disorders treated by amphetamine.Results: On 6 August 2023, a search of the ClinicalTrials.gov database with the term “amphetamines” identified 179 clinical trials. After extensive exclusion criteria, 19 trials were ultimately selected for analysis. The predominant condition under investigation was attention deficit hyperactivity disorder (ADHD), present in 84.2% of studies. Key study characteristics included: phase 4 trials (36.8%), randomized allocation (63.2%), and the parallel intervention model (42.1%). Masking techniques varied, with no masking in 42.1% of studies, and double and quadruple masking both accounting for 21.1%. Geographically, 78.9% of the studies’ participants were from the United States.Conclusion: This study highlights the notable therapeutic potential of amphetamines in pediatric ADHD populations and emphasizes the importance of recognizing potential side effects and addiction risks. As pharmacogenomics offers the prospect of personalized treatments, there is potential to increase therapeutic efficacy and decrease adverse reactions. It is vital to balance these benefits against the inherent risks, understanding the need for continued research to optimize the use of amphetamines in medicine.

【 授权许可】

Unknown   
Copyright © 2023 Alalalmeh, Hegazi, Shahwan, Alshehri, Ashour, Algarni and Alorfi.